Abstract:Summary Background Sarcoidosis is an inflammatory condition that can affect various organs and tissues, causing the formation of granulomas and subsequent functional impairment. The origin of sarcoidosis remains unknown and there are few treatment options. Mechanistic target of rapamycin (mTOR) activation is commonly seen in granulomas of patients across different tissues and has been shown to induce sarcoidosis-like granulomas in a mouse model. This study aimed to examine the efficacy and safety of the mTOR inhibitor sirolimus as a treatment for cutaneous sarcoidosis. Methods We did a single-centre, randomised study treating patients with persistent and glucocorticoid-refractory cutaneous sarcoidosis with sirolimus at the Vienna General Hospital, Medical University of Vienna (Vienna, Austria). We recruited participants who had persistent, active, and histologically proven cutaneous sarcoidosis. We used an n-of-1 crossover design in a placebo-controlled, double-blind topical treatment period and a subsequent single-arm systemic treatment phase for 4 months in the same participants. Participants initially received either 0·1% topical sirolimus in Vaseline or placebo (Vaseline alone), twice daily. After a washout period, all participants were subsequently administered a 6 mg loading dose followed by 2 mg sirolimus solution orally once daily, aiming to achieve serum concentrations of 6 ng/mL. The primary endpoint was change in the Cutaneous Sarcoidosis Activity and Morphology Index (CSAMI) after topical or systemic treatment. All participants were included in the safety analyses, and patients having completed the respective treatment period (topical treatment or systemic treatment) were included in the primary analyses. Adverse events were assessed at each study visit by clinicians and were categorised according to their correlation with the study drug, severity, seriousness, and expectedness. This study is registered with EudraCT (2017-004930-27) and is now closed. Findings 16 participants with persistent cutaneous sarcoidosis were enrolled in the study between Sept 3, 2019, and June 15, 2021. Six (37%) of 16 participants were men, ten (63%) were women, and 15 (94%) were White. The median age of participants was 54 years (IQR 48–58). 14 participants were randomly assigned in the topical phase and 2 entered the systemic treatment phase directly. Daily topical treatment did not improve cutaneous lesions (effect estimate –1·213 [95% CI –2·505 to 0·079], p=0·066). Systemic treatment targeting trough serum concentrations of 6 ng/mL resulted in clinical and histological improvement of skin lesions in seven (70%) of ten participants (median –7·0 [95% CI –16·5 to –3·0], p=0·018). Various morphologies of cutaneous sarcoidosis, including papular, nodular, plaque, scar, and tattoo-associated sarcoidosis, responded to systemic sirolimus therapy with a long-lasting effect for more than 1 year after treatment had been stopped. There were no serious adverse events and no deaths. Interpretation Short-term treatment with systemic sirolimus might be an effective and safe treatment option for patients with persistent glucocorticoid-refractory sarcoidosis with a long-lasting disease-modulating effect. The effect of sirolimus in granulomatous inflammation should be investigated further in large, multi-centre, randomised clinical trials. Funding Vienna Science and Technology Fund, Austrian Science Fund.

Hydroxychloroquine monotherapy in sarcoidosis: Indications, efficacy, and side effects

Treatment of subcutaneous sarcoidosis with hydroxychloroquine: report of 2 cases

How to Use and Monitor Sarcoidosis Medications

ERS clinical practice guidelines on treatment of sarcoidosis

In sarcoidosis trials, time also matters

Five principles and protocols for the clinician based on the 2021 ERS and BTS statements for treating sarcoidosis

Hepatic sarcoidosis:an Italian multicenter study

Progress of Inhaled Corticosteroids in Treatment of Pulmonary Sarcoidosis

Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial

Delphi Consensus Recommendations for a Treatment Algorithm in Pulmonary Sarcoidosis

Sarcoidosis of the central nervous system: Safety and efficacy of treatment, and experience of biological therapies

Interventional Therapy in Sarcoidosis-Associated Pulmonary Arterial Stenosis and Pulmonary Hypertension

Clinical application and long-term safety of hydroxychloroquine in rheumatic diseases

AB0373 Treatment of Primary Sjogren’s Syndrome-Associated Lung Disease: a Prospective Study

Role of anti-tumor necrosis factor-alpha agents in treatment of sarcoidosis: A meta-analysis

Evaluating corticosteroid treatment strategies for cardiac sarcoidosis: analysis of the nationwide claims-based JROAD-DPC dataset

Diagnostics, treatment and outcomes of cardiac sarcoidosis in a Norwegian cohort

The role of vitamin D in sarcoidosis

Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records

Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis

Hydroxychloroquine in systemic lupus erythematosus (SLE)